Ohio is currently home to 3219 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Impact of Defecation Posture on Ease of Bowel Movements in Patients With a Rectocele
NCT06252714
Recruiting
The study aims to determine if defecation posture, when using a defecation posture modification device (DPMD), will improve ease of bowel movements in patients with pelvic organ prolapse, specifically rectoceles.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Cincinnati Urogynecology Associates, Cincinnati, Ohio
Conditions: Pelvic Organ Prolapse, Rectocele, Bowel Dysfunction
Register for Updates
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
NCT06029660
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: TriHealth Heart Institute, Cincinnati, Ohio
Conditions: Aortic Aneurysm, Abdominal
Register for Updates
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428
Recruiting
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Bexley, Ohio, Bexley, Ohio
Conditions: Alopecia Areata
Register for Updates
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
NCT05715281
Recruiting
This phase II trial tests how well atezolizumab works in combination with tiragolumab in treating patients with rare solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced stage). Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The study biopsy takes small pieces of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
Register for Updates
Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
NCT05706311
Recruiting
This goal of this observational study is to develop and test the Opioid Risk Reduction Clinical Decision Support (ORRCDS) tool. The tool will be an opioid medication risk screener and decision support platform that will be used by pharmacists upon dispensing prescription opioid medication. Once the Opioid Risk Reduction has been developed, we will examine the impact of the ORRCDS within two divisions of a large chain retail pharmacy. Pharmacies will be randomized to using the Opioid Risk Reducti... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/16/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Opioid Abuse, Prescription Opioid Abuse
Register for Updates
Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age
NCT05345457
Recruiting
A randomized, controlled, non-placebo trial to primarily assess the effect of oral, outpatient antibiotics (i.e., azithromycin and amoxicillin) on latency (i.e., proportion of patients that deliver within 28 days from membrane rupture) following previable, prelabor rupture of membranes between 18 0/7 and 22 6/7 weeks gestational age.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University Hospitals, Cleveland, Ohio
Conditions: Pregnancy Preterm, Pregnancy Prom, PROM, Preterm (Pregnancy), PROM (Pregnancy), Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/Labor, Premature Birth
Register for Updates
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
NCT03033992
Recruiting
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
04/16/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06803888
Recruiting
The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) distributed in various organs. These medications provide an average of 15-22% weight redu... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: The Cleveland Clinic, Cleveland, Ohio
Conditions: Obesity and Obesity-related Medical Conditions
Register for Updates
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Recruiting
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
04/15/2025
Locations: Velocity Clinical Research, Beachwood, Ohio
Conditions: Female Contraception
Register for Updates
Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
NCT06671002
Recruiting
This trial is being completed to compare two commonly used options to treat pain after discharge from surgery. Participants that undergo tonsil removal, gallbladder removal, and knee scope will be eligible to enroll. Eligible participants will be randomized to prescription of 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) plus acetaminophen or low dose opioids with the NSAIDs plus acetaminophen. The key question the study seeks to answer is which option will have th... Read More
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
04/15/2025
Locations: Nationwide Children's (NCH), Columbus, Ohio
Conditions: Surgery, Pain, Post Operative
Register for Updates
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
Recruiting
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Bexley Dermatology Research - Probity - PPDS, Bexley, Ohio
Conditions: Plaque Psoriasis
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Cole Eye Institute, Cleveland, Ohio
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates